{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:53:19Z","timestamp":1794001999533,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-6KP"],"award-info":[{"award-number":["CA209-6KP"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02332-8","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:59:20Z","timestamp":1747270760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring"],"prefix":"10.1186","volume":"24","author":[{"given":"Heng","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuning","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoyan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"3","key":"2332_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"2332_CR2","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384.","journal-title":"N Engl J Med"},{"issue":"8","key":"2332_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","volume":"156","author":"H Yang","year":"2021","unstructured":"Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156(8):721\u20139.","journal-title":"JAMA Surg"},{"issue":"10447","key":"2332_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404(10447):55\u201366.","journal-title":"Lancet"},{"issue":"2","key":"2332_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","volume":"34","author":"H Tang","year":"2023","unstructured":"Tang H, Wang H, Fang Y, Zhu JY, Yin J, Shen YX, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol. 2023;34(2):163\u201372.","journal-title":"Ann Oncol"},{"issue":"30","key":"2332_CR6","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","volume":"27","author":"WH Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2332_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68\u201374.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2332_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20(3):343\u201372.","journal-title":"Esophagus"},{"issue":"11","key":"2332_CR9","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317.","journal-title":"Lancet Oncol"},{"issue":"35","key":"2332_CR10","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal Cancer. J Clin Oncol. 2020;38(35):4138\u201348.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2332_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"},{"issue":"21","key":"2332_CR12","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung Cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"6","key":"2332_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonzalez-Larriba JL, Martinez-Marti A, Bernabe R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III Non-Small-Cell lung Cancer. N Engl J Med. 2023;389(6):504\u201313.","journal-title":"N Engl J Med"},{"issue":"4suppl","key":"2332_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JCO.2019.37.4_suppl.142","volume":"37","author":"RJ Kelly","year":"2019","unstructured":"Kelly RJ, Smith KN, Anagnostou V, Thompson E, Hales RK, Battafarano RJJ, et al. Neoadjuvant nivolumab plus concurrent chemoradiation in stage II\/III esophageal\/gastroesophageal junction cancer. J Clin Oncol. 2019;37(4suppl):142.","journal-title":"J Clin Oncol"},{"key":"2332_CR15","doi-asserted-by":"crossref","unstructured":"Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3).","DOI":"10.1136\/jitc-2021-004291"},{"issue":"9","key":"2332_CR16","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med. 2024;30(9):2549\u201357.","journal-title":"Nat Med"},{"issue":"13","key":"2332_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction Cancer. N Engl J Med. 2021;384(13):1191\u2013203.","journal-title":"N Engl J Med"},{"issue":"7","key":"2332_CR18","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1097\/JS9.0000000000001373","volume":"110","author":"H Zhang","year":"2024","unstructured":"Zhang H, Jin T, Peng Y, Luan S, Li X, Xiao X, et al. Association between plasma Circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis. Int J Surg. 2024;110(7):4370\u201381.","journal-title":"Int J Surg"},{"issue":"7957","key":"2332_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al. Tracking early lung cancer metastatic dissemination in tracerx using ctdna. Nature. 2023;616(7957):553\u201362.","journal-title":"Nature"},{"issue":"2","key":"2332_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229\u201339.","journal-title":"Ann Oncol"},{"issue":"1","key":"2332_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127\u201334.","journal-title":"Nat Med"},{"issue":"1","key":"2332_CR22","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41467-024-46307-7","volume":"15","author":"B Chen","year":"2024","unstructured":"Chen B, Liu S, Zhu Y, Wang R, Cheng X, Chen B, et al. Predictive role of ctdna in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with Toripalimab. Nat Commun. 2024;15(1):1919.","journal-title":"Nat Commun"},{"issue":"4","key":"2332_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctdna analyses. Nat Med. 2024;30(4):1023\u201334.","journal-title":"Nat Med"},{"issue":"2","key":"2332_CR24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.21037\/jtd-22-1789","volume":"15","author":"J Yin","year":"2023","unstructured":"Yin J, Lin S, Fang Y, Jiao H, Chen Z, Tang H, et al. Neoadjuvant therapy with Immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). J Thorac Dis. 2023;15(2):718\u201330.","journal-title":"J Thorac Dis"},{"issue":"10","key":"2332_CR25","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","volume":"41","author":"K Chen","year":"2023","unstructured":"Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, et al. Individualized tumor-informed Circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer Cell. 2023;41(10):1749\u201362. e6.","journal-title":"Cancer Cell"},{"issue":"16","key":"2332_CR26","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2332_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80\u201392.","journal-title":"Fly (Austin)"},{"issue":"2","key":"2332_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.bjc.6601118","volume":"89","author":"TG Clark","year":"2003","unstructured":"Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89(2):232\u20138.","journal-title":"Br J Cancer"},{"issue":"7636","key":"2332_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"U Asan","year":"2017","unstructured":"Cancer Genome Atlas Research N, Analysis Working Group, Asan U, Agency BCC, Brigham, Women\u2019s H, Broad I, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169\u201375.","journal-title":"Nature"},{"issue":"1","key":"2332_CR30","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/s41467-023-37440-w","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Jiang D, Zhang Q, Liu H, Xu F, Guo C, et al. Integrative proteogenomic characterization of early esophageal cancer. Nat Commun. 2023;14(1):1666.","journal-title":"Nat Commun"},{"issue":"19","key":"2332_CR31","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung Cancer. N Engl J Med. 2024;390(19):1756\u201369.","journal-title":"N Engl J Med"},{"key":"2332_CR32","doi-asserted-by":"crossref","unstructured":"Loi S, Curigliano G, Salgado RF, Romero Diaz RI, Delaloge S, Rojas C, et al. LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) \u00b1 NIVO in patients(pts) with high-risk, ER\u2009+\u2009HER2\u2212 primary breast cancer (BC). Annals of Oncology.2023;34:S1259-S60.","DOI":"10.1016\/j.annonc.2023.10.010"},{"issue":"3","key":"2332_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"AO Kaseb","year":"2022","unstructured":"Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208\u201318.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"2332_CR34","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/1759-7714.14795","volume":"14","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li H, Chen X, Qin J, Li Y, Shen Y, et al. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus Paclitaxel plus immunotherapy for esophageal squamous cell carcinoma. Thorac Cancer. 2023;14(7):700\u20138.","journal-title":"Thorac Cancer"},{"issue":"5","key":"2332_CR35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jamasurg.2021.0133","volume":"156","author":"H Wang","year":"2021","unstructured":"Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, et al. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: A randomized clinical trial. JAMA Surg. 2021;156(5):444\u201351.","journal-title":"JAMA Surg"},{"key":"2332_CR36","doi-asserted-by":"publisher","first-page":"e066381","DOI":"10.1136\/bmj-2021-066381","volume":"375","author":"F Conforti","year":"2021","unstructured":"Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381.","journal-title":"BMJ"},{"issue":"1","key":"2332_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch JS, Cimino-Mathews A, Thompson E, Provencio M, Forde PM, Spicer J, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024;30(1):218\u201328.","journal-title":"Nat Med"},{"issue":"7","key":"2332_CR38","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/ijc.34636","volume":"153","author":"P Marolleau","year":"2023","unstructured":"Marolleau P, Tougeron D, Allignet B, Cohen R, Sefrioui D, Gallet B, et al. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: results of a retrospective multicenter study. Int J Cancer. 2023;153(7):1376\u201385.","journal-title":"Int J Cancer"},{"issue":"12","key":"2332_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2332_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to Anti-PD Cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2332_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","volume":"158","author":"TD Azad","year":"2020","unstructured":"Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal Cancer. Gastroenterology. 2020;158(3):494\u2013505. e6.","journal-title":"Gastroenterology"},{"issue":"2","key":"2332_CR42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","volume":"30","author":"JC Murray","year":"2024","unstructured":"Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, et al. Elucidating the heterogeneity of immunotherapy response and immune-Related toxicities by longitudinal ctdna and immune cell compartment tracking in lung Cancer. Clin Cancer Res. 2024;30(2):389\u2013403.","journal-title":"Clin Cancer Res"},{"key":"2332_CR43","doi-asserted-by":"crossref","unstructured":"Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022;10(6).","DOI":"10.1136\/jitc-2022-004688"},{"key":"2332_CR44","doi-asserted-by":"crossref","unstructured":"Xu L, Si H, Zhuang F, Li C, Zhang L, Zhao Y et al. Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024.","DOI":"10.1016\/j.jtcvs.2024.05.006"},{"issue":"1","key":"2332_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-024-02006-x","volume":"23","author":"P Yue","year":"2024","unstructured":"Yue P, Bie F, Zhu J, Gao LR, Zhou Z, Bai G, et al. Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma. Mol Cancer. 2024;23(1):96.","journal-title":"Mol Cancer"},{"issue":"11","key":"2332_CR46","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamasurg.2023.4395","volume":"158","author":"HY Ng","year":"2023","unstructured":"Ng HY, Ko JMY, Lam KO, Kwong DLW, Lo AWI, Wong IYH, et al. Circulating tumor DNA dynamics as prognostic markers in locally advanced and metastatic esophageal squamous cell carcinoma. JAMA Surg. 2023;158(11):1141\u201350.","journal-title":"JAMA Surg"},{"issue":"11","key":"2332_CR47","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1002\/ctm2.1116","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Yu N, Cheng G, Zhang T, Wang J, Deng L, et al. Prognostic value of Circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. Clin Transl Med. 2022;12(11):e1116.","journal-title":"Clin Transl Med"},{"issue":"23suppl","key":"2332_CR48","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.2024.42.23_suppl.196","volume":"42","author":"Z Li","year":"2024","unstructured":"Li Z, Yang Y, Liu Z, Gao X, Wilk BVd, Chao Y, et al. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): A prospective multicenter diagnostic cohort study in Asia. J Clin Oncol. 2024;42(23suppl):196.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2332_CR49","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/cac2.12494","volume":"43","author":"SQ Yuan","year":"2023","unstructured":"Yuan SQ, Nie RC, Huang YS, Chen YB, Wang SY, Sun XW, et al. Residual Circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Cancer Commun (Lond). 2023;43(12):1312\u201325.","journal-title":"Cancer Commun (Lond)"},{"issue":"6680","key":"2332_CR50","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1126\/science.adn1886","volume":"383","author":"T Moser","year":"2024","unstructured":"Moser T, Heitzer E. Surpassing sensitivity limits in liquid biopsy. Science. 2024;383(6680):260\u20131.","journal-title":"Science"},{"issue":"6680","key":"2332_CR51","doi-asserted-by":"publisher","first-page":"eadf2341","DOI":"10.1126\/science.adf2341","volume":"383","author":"C Martin-Alonso","year":"2024","unstructured":"Martin-Alonso C, Tabrizi S, Xiong K, Blewett T, Sridhar S, Crnjac A, et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies. Science. 2024;383(6680):eadf2341.","journal-title":"Science"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02332-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02332-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02332-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T02:02:34Z","timestamp":1747274554000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02332-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2332"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02332-8","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The primary protocol and all amendments received approval from the Institutional Review Board (IRB) of Zhongshan Hospital affiliated with Fudan University (B2022-004R) and from the IRBs of each participating institution. The study was performed following the Declaration of Helsinki and adhered to international standards of good clinical practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All sample collection procedures adhered to standard clinical protocols, and written informed consent was obtained prior to the sample collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lijie Tan reported that the study was funded by Bristol-Myers Squibb (CA209-6KP). The other authors declared no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}